BioCryst Pharmaceuticals announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance, pCPA, for oral, once-daily PrORLADEYO, which is approved in Canada for the routine prevention of attacks of hereditary angioedema, HAE, in adults and pediatric patients 12 years of age and older. “The completion of the negotiations with pCPA mark a critical step in bringing ORLADEYO to patients with HAE through the public health system in Canada. In a relatively short amount of time, we have made significant progress, including securing approval of ORLADEYO from Health Canada and receiving positive recommendations from Canada’s Drug Agency and INESSS,” said Anand Janack, vice president and general manager of BioCryst Canada.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
- BioCryst presents first interim real-word evidence from APeX-N trial
- BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
- BioCryst appoints Fong as Chief Medical Officer
- BioCryst reports inducement grants under Nasdaq listing rule
Questions or Comments about the article? Write to editor@tipranks.com